SSR240600C Treatment in Women With Overactive Bladder

Completed · Phase 2 · Has a placebo group

Conditions studied: Overactive Bladder

In brief

The primary objective of this study is to evaluate the efficacy of SSR240600C in women with overactive bladder compared to placebo using tolterodine as a study calibrator.

Key facts

Study ID

NCT00564226

Run by

Sanofi

People needed

345

Starts

2007-11-01

Expected to finish

2009-02-01

Last updated by the study team

2016-05-26

Who can join

Age: 18 and older, up to 70. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of overactive bladder

You may not qualify if…

• Stress incontinence or mixed incontinence where stress incontinence is the predominant component based on prior history
• Urinary incontinence due to cause other than detrusor overactivity (eg, overflow incontinence)
• Current Urinary Tract Infection (UTI) or frequent UTIs
• Urinary retention or other evidence of poor detrusor function
• Pain during voiding or bladder pain without voiding
• History of radiation cystitis or history of pelvic irradiation
• History of interstitial cystitis or bladder related pain syndrome
• The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Where it is running

• Sanofi-Aventis Aministrative Office — Bridgewater, New Jersey, United States
• Sanofi-Aventis Administrative Office — Laval, Quebec, Canada
• Sanofi-Aventis Administrative Office — Prague, Czechia
• Sanofi-Aventis Administrative Office — Paris, France
• Sanofi-Aventis Administrative Office — Berlin, Germany
• Sanofi-Aventis Administrative Office — Gouda, Netherlands
• Sanofi-Aventis Administrative Office — Porto Salvo, Portugal

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.